16. Commitments and Contingencies The Company s long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. These include commitments related to purchases of inventory of the Company s products, research and development service agreements, operating leases and selling, general and administrative obligations, increases to the Company s restricted cash in connection with its new principal office space in Parsippany, New Jersey, and royalty and milestone payments due. Future estimated contractual obligations as of December 31, 2010 are: Contractual Obligations 2011 2012 2013 2014 2015 Later Years Total (In thousands) Inventory related commitments $ 30,316 $ 14,669 $   $   $   $   $ 44,985 Research and development 26,419 19,234 320 119 65   46,157 Operating leases 8,870 8,035 6,346 5,006 4,623 34,021 66,901 Selling, general and administrative 3,092 1,826 216       5,134 Unrecognized tax benefits 1,891           1,891 Total contractual obligations $ 70,588 $ 43,764 $ 6,882 $ 5,125 $ 4,688 $ 34,021 $ 165,068 All of the inventory related commitments included above are non-cancellable. Included within the inventory related commitments above are purchase commitments to Lonza Braine totaling $25.3 million for 2011 and $14.7 million for 2012 for Angiomax bulk drug substance. Of the total estimated contractual obligations for research and development and selling, general and administrative activities, $8.9 million is non-cancellable. The Company leases its principal offices in Parsippany, New Jersey. The lease covers 173,146 square feet and expires January 2024. The lease for the Company s old office facility in Parsippany expires January 2013. In the second half of 2009, the Company subleased this previous old office space to two tenants. The first sublease, for the second floor of that office space, expires in March 2011 and the second sublease, covering the first floor of the Company s previous office space, expires in January 2013. Additionally,